SVB Securities

Wellvana is a healthcare company that focuses on creating a clinically integrated network platform to enhance coordination across the continuum of care. Founded in 2018 and headquartered in Nashville, Tennessee, Wellvana develops solutions that facilitate real-time decision-making and manage patient flow within the healthcare system. The company provides a high-touch approach to value-based care, allowing independent physicians and health systems to maintain their autonomy while reducing administrative burdens. This enables them to devote more time to patient care and improve health outcomes. Wellvana partners with primary care providers, specialists, and hospitals across 23 states, managing lives through various payor partnerships, including Medicare and commercial payors. The company has experienced significant growth, supporting over 1,000 physicians in assuming downside risk while promoting financial stability through innovative payment models. Wellvana's commitment to coordinated care aims to transform the patient experience and drive healthier profitability for healthcare providers.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Umoja Biopharma specializes in innovative immunotherapy aimed at transforming cancer treatment and enhancing patient quality of life. The company focuses on reprogramming T cells within the patient's body to effectively target cancer, including solid tumors and hematological cancers that often have poor responses to conventional therapies. Its proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens tailored to various stages of cancer, enabling medical practitioners to directly and safely attack cancer cells. By harnessing the body's immune response, Umoja Biopharma seeks to improve overall patient outcomes and provide more effective treatment options for those affected by cancer.

Locanabio, Inc. is a biotechnology company based in San Diego, California, founded in 2016. It specializes in developing RNA-targeted gene therapies aimed at treating a range of underserved diseases, particularly in the areas of neuromuscular, neurodegenerative, and retinal conditions. The company's innovative platform focuses on modifying disease-causing RNA, allowing for the identification and correction of specific RNA sequences associated with rare genetic disorders. This approach distinguishes Locanabio's therapies from traditional DNA-targeted methods, offering a unique solution for patients with severe and challenging health issues. The company, which rebranded from Locana, Inc. in July 2020, is dedicated to advancing therapeutic candidates that address significant medical needs.

Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for patients suffering from obstructive sleep apnea (OSA). Founded in 2007 and headquartered in Golden Valley, Minnesota, the company specializes in innovative implantable neurostimulation technologies. Its primary product, the Inspire system, utilizes a proprietary Upper Airway Stimulation (UAS) therapy that provides a safe and effective treatment for moderate to severe OSA. This technology leverages established principles from cardiac pacing and neurostimulation to deliver mild hypoglossal nerve stimulation, which helps maintain an open airway by continuously monitoring the patient's breathing. Inspire Medical Systems operates primarily in the United States and Europe, generating most of its revenue from the U.S. market.